Review

The Possibility of Assessing Pain with Biomarkers in Psychiatric Disorders

Piotr Jakubow 1,* , Urszula Kościuczuk 2, Adam Garkowski 3, Aleksander Turczynowicz 4, Łukasz Skowroński 5, Mojsak Małgorzata 3

1 Children and Adolescents Department of Anaesthesia and Intensive Care and Pain Therapy Unit, Department of Palliative Medicine, Medical University of Białystok 15-215, Poland. piotr.jakubow@umb.edu.pl *
2 Department of Anaesthesiology and Intensive Therapy, Medical University of Białystok 15-215; Poland urszula.kosciuczuk@umb.edu.pl
3 Department of Radiology, Independent Department Laboratory of Molecular Imaging. Medical University of Białystok 15-215, Poland; adam.garkowski@gmail.com, malgorzata.mojsak@umb.edu.pl
4 Medical University of Białystok 15-215, Poland; aturczynowic1@student.umb.edu.pl
5 Medical University of Białystok 15-215, Poland; skowronski.lukasz1989@gmail.com

* Correspondence: piotr.jakubow@umb.edu.pl; Tel.: +48-8-5746-8449

Abstract: According to the literature, patients with chronic pain and mental disorders constitute a huge, heterogeneous group. However, it is known that social and psychological processes closely affect the level and expression of chronic pain.

In this paper, we present a review of the literature, define methods of identifying pain biomarkers and consider the possibility of using them to assess pain in mental disorders. Group researchers searched PubMed, Scope, and Cochrane databases for "pain biomarkers in mental disorders" between 2011 and 2021. for available databases for full-text, peer-reviewed studies and review publications using the following keywords: pain biomarkers, neuroimaging pain, pain metabolomics, pain and psychiatric disorders, pain electroencephalography (EEG), serum pain biomarkers, saliva biomarkers, and diagnosis pain. The search included full-text articles, clinical trials, randomized controlled trials, and systematic reviews. Was used part of the PRISMA method to review the literature systematically. A literature search identified 283 studies based on the initially set inclusion and exclusion criteria. In the subsequent selection stages, 11 studies were selected for analysis. There are three main areas of the possible use of biomarkers for the clinical assessment of pain in psychiatric patients, neuroimaging, changes in metabolite levels in body fluids, and changes in gene expression. As a result of the review, individual pain mediators were distinguished that may be markers of pain in psychiatric patients. Some mediators indicate the specificity of pain and are of diagnostic importance. However, despite significant advances in research, most of the described biomarkers found in clinical trials assessing the severity and frequency of pain have no practical significance in psychiatric disorders. It is possible to diagnose pain based on neuroimaging using various methods, genetic methods, body fluids: blood and urine. Of the many, body fluid biomarkers are the most advanced. Discussion: Biomarker research is a dynamically developing field. The review has proposed new ways to diagnose pain by identifying pain biomarkers. Work presented pain diagnostics in psychiatric disorders based on biomarkers from various neuroimaging methods, blood and urine analysis. The possibility of new, effective techniques gives hope for the correct diagnosis of pain, especially in patients with mental disorders.
disorders, which would allow for appropriate and adequate therapeutic therapies. In clinical practice is limited to a few methods. Assessment of pain biomarkers in body fluids (serum, saliva, and urine) seems to be the most practical and promising method of clinical application.

Conclusions: There are new techniques that give hope for the correct diagnosis of pain, especially in patients with mental disorders, which will allow for their proper and adequate therapy. According to the literature, patients with chronic pain and mental disorders constitute a huge, heterogeneous group. However, it is known that social and psychological processes closely affect the level and expression of chronic pain.

1. Introduction

Pain is one of many symptoms and major comorbidities of psychiatric patients, including those with psychosomatic and somatic disabilities [1,2]. According to epidemiological data, chronic pain affects up to 20% of the world’s population and contributes significantly to the somatic impairment of patients with psychiatric disorders [3,4].

A working group of the International Association for the Study of Pain has developed a new classification of chronic pain for the International Classification of Diseases ICD-11 [5,6]. Chronic pain is defined as pain that persists or recurs for more than three months and may be conceived as a disease in its own right as “chronic primary pain” or related to other diseases as “chronic secondary pain” [6,7]. According to the literature, patients with chronic pain and psychiatric disorders are a huge heterogeneous group [7].

It has been reported that social and psychological processes impact the level and expression of chronic pain. In addition, there is evidence that chronic pain is associated with mental disorders and addiction to pain medications [8,9]. Patients with chronic pain and mental illness may suffer from affective disorders such as depression, personality impairment, dependence on analgesics, and various somatic disorders such as hypochondria [8,9]. There are also disorders that may be secondary to chronic pain, may precede the onset of pain, or may occur simultaneously, increasing the occurrence of both pain and mental impairment [9,10]. Recognition of pain is important as it influences treatment options and medication types [11].

Inadequate pain management methods can cause therapeutic complications and serious clinical problems, often including pain syndrome following incorrectly qualified invasive procedures and the lack of diagnosis of psychiatric disorders in somatic diseases. The most common problem is the excessive use of opioids, which has led to the opioid crisis in the US and Europe. Due to inadequate pain diagnosis, patients may have used strong painkillers such as opioids, although they should not be prescribed; therefore, in patients with substance use disorders (SUD) and other underlying psychiatric illnesses, proper pain diagnosis is essential.

Regardless of their etiological significance, any incorrect diagnosis may, as a result, increase pain and hinder recovery. [5].

The question arose whether it is possible to distinguish pain biomarkers in mental diseases so that its specific treatment can be applied in the future.

2. Methods

Following part of PRISMA guidelines, a structured electronic search of the literature was conducted in the PubMed, Scopus, and Cochrane databases figure 1. Eligible studies included the following criteria: (1) studies that analyzed pain assessment using biomarkers, (2) studies on pain assessment in patients with mental illnesses, (3) studies on assessment
neuroimaging and biomarkers in body fluids, and (4) studies published in peer-reviewed journals from 2011 to 2021. (5) The articles included peer-reviewed studies and review publications using the following keywords: pain biomarkers, pain neuroimaging, pain metabolomics, pain and psychiatric disorders, pain electroencephalography (EEG), serum pain biomarkers, saliva biomarkers, pain diagnosis, clinical pain assessment, mobile applications. Full-text articles, clinical studies, randomized controlled trials, and systematic reviews, were included in the search.

Articles on pain in children and adolescents, articles published without reviews, articles from popular science magazines, and editorials were excluded. No grey literature was included in the search and articles were independently reviewed for inclusion by two researchers who rated the quality of the articles.

Two researchers collected literature, and others checked the validity of the conclusions. The aim was to identify the necessary knowledge and practical diagnostic methods to determine specific pain biomarkers in mental disorders. To describe the specific features that are biomarkers of pain in psychiatric patients, it has been assumed that it is possible to apply determinations in the central nervous system, both through neuroimaging and other tests, as well as in body fluids, including cerebrospinal fluid, serum, urine, and saliva.

The Prisma analysis was not performed in full, the BIAS risk was not determined, and the obtained articles were described descriptively, not statistically. However, the entire material obtained was included in the analysis tab.1.

Table 1. The table shows studies included in qualitative synthesis.

<table>
<thead>
<tr>
<th>Reference studies included in synthesis</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>The search for pain biomarkers in the human brain, Brain, 2018;141,(12), 3290–3307, doi.org/10.1093/brain/awy281</td>
<td>Mouraux, A;</td>
</tr>
<tr>
<td>Study Title</td>
<td>Authors</td>
</tr>
<tr>
<td>----------------------------------------------------------------------------</td>
<td>------------------</td>
</tr>
<tr>
<td>Towards precision medicine for pain: Diagnostic biomarkers and</td>
<td>Niculescu, A.B.</td>
</tr>
<tr>
<td>repurposed drugs. Mol. Psychiatry 2019, 24, 501–522, doi:10.1038/s41380-</td>
<td></td>
</tr>
<tr>
<td>0-018-0345-5.</td>
<td></td>
</tr>
<tr>
<td>Reduced Glutamate in the Medial Prefrontal Cortex Is Associated With</td>
<td>Naylor B,</td>
</tr>
<tr>
<td>Emotional and Cognitive Dysregulation in People With Chronic Pain. Front</td>
<td></td>
</tr>
<tr>
<td>Randomized Trial on the Clinical Utility of a Novel Biomarker Panel to</td>
<td>Peabody, J.</td>
</tr>
<tr>
<td>Determinants of Chronic Pain. Diagnostics (Basel). 2020;10(8):513. doi:</td>
<td></td>
</tr>
<tr>
<td>10.3390/diagnostics10080513</td>
<td></td>
</tr>
<tr>
<td>Clinical Validation of a Multi-Biomarker Assay for the Evaluation of</td>
<td>Amirdelfan, K.</td>
</tr>
<tr>
<td>Chronic Pain Patients in a Cross-Sectional, Observational Study. Pain</td>
<td></td>
</tr>
<tr>
<td>Neuroinflammation, Pain and Depression: An Overview of the Main Findings.</td>
<td>Campos, A.C.P.</td>
</tr>
<tr>
<td>32849076; PMCID: PMC7412934.</td>
<td></td>
</tr>
</tbody>
</table>
Figure 1. PRISMA Flow Diagram for pain biomarkers in psychiatry 2011-2021

Records identified through pub-med database searching (n = 223)

Additional records identified through scope and Cochrane (n = 163)

Records after duplicates removed (n = 289)

Records excluded (n = 238)

Records screened (n = 51)

Full-text articles assessed systematic review for eligibility (n = 26)

Full-text articles excluded, with reasons not meet criteria (n = 25)

Studies included in qualitative synthesis (n = 11)

Figure 1. PRISMA diagram. The PRISMA method was used to systematically review the literature. We found 223 references in the pubmed database, 160 publications in the scope, and 2 analyses in the Cochrane database matching the pain criteria searched by the presence of mediators in psychiatry. After excluding redundant entries, 289 items remained, of which 238 did not meet the criteria. After the second analysis, 26 items were included in the study, from which 11 items were finally selected that fully describe the possibilities of using biomarkers in the assessment of pain.
Results: Biomarkers in Clinical Pain Assessment

The diagnosis and differentiation of pain in practice is currently based on a patient’s history and clinical symptoms, as well on pain assessment scales. There are many types of pain assessment widely used for detecting and quantifying pain.

Generally, batteries of pain tests are divided into two categories, i.e., visual analogy scales (VASs) in which patients indicate their pain level by marking the level on a scale, and numerical scales (NRSs) in which patients self-assess their pain using specific numbers that represent the level of pain experienced; usually, both categories are quantitative scales. The scales are both used to help improve communication between a physician and a patient during therapy and subsequent visits [11,12].

The most comprehensive assessments use certain adjectives as a tool to describe pain, and they can also use numbers, colors, body positions, and facial expressions to describe a certain type of pain. These are qualitative scales that may be used, in part, to determine the cause of the pain and the underlying health problems from which the pain arises [12,13]. Recent studies have demonstrated that software applications (mobile apps) that run on smartphones with traditional pain scales are useful for assessing pain. The use of mobile apps, which are accessible almost 24/7, is particularly helpful in an outpatient setting. A mobile-application-based intervention study demonstrated that pain apps can be useful for reducing pain among cancer and non-cancer pain patients [14–16].

In addition to our literature search, we searched for mobile applications that have been introduced for the identification of mental disorders, and which are considered to improve the contact and supervision of patients with both chronic pain and mental disorders [17,18] It's worth to mention that there are mobile applications introduced to identify mental disorders and considered as an improvement in contact and supervision with patients suffering not only from mental disorders per se, but also from chronic pain disorders as well. Those mobile apps however cannot be considered as biomarker, so they were not included in this review. There have also been studies on pain assessment based on facial expressions; algorithms use machine learning to automatically recognize physical expressions of pain. Despite advanced work, these assessment methods are not widely available; however, this technology is useful for evaluating children and patients who are unaware of their condition [19,20].

Individual pain assessment tools structured as scales are usually designed to assess a specific group of patients. There is a huge range of tools available for assessing neuro-pathic pain, including the Neuropathic Pain Questionnaire, Leeds Assessment of Neuro-pathic Symptoms, painDETECT questionnaire, Douleur Neuropathique 4 Questions (DN4), and many others. At the same time, specifically constructed tools such as the Fibromyalgia Survey Questionnaire, Comprehensive Regional Pain Syndrome Questionnaire, Headache Questionnaire, and Migraine Disability Assessment Test [20] are used to classify individual pain units. This type of assessment tool is commonly used in practice. All of these behavioral scales are subjective, and one such test may not reflect the appropriate intensity of pain, let alone the cause of the pain and the objective confirmation of its existence.

In addition, even the best subjective pain scales cannot confirm if the pain really exists or is merely an image of the pain caused by consciousness. Another important factor in pain treatment is knowing to what extent the pain experienced by a patient is subjectively aggravated by their emotions.
An important tool that combines the assessment of chronic pain and psychosocial state is the Multidimensional Pain Inventory (MPI), a questionnaire used to connect various categories of chronic pain to patients’ psychosocial characteristics [21].

Concurrent with pain assessment studies, the intensity of emotions is assessed, but a diagnosis cannot easily be made based on a single visit and requires observation and long-term cooperation with a patient [22]. In parallel, identifying and treating any mental disorders or substance-use problems that may occur is essential for the successful rehabilitation of people with chronic pain [9].

In the case of chronic pain, the severity of pain is determined by the state of the human psyche, and therefore scales assessing the impact of emotions and cognitive functions on the perception of pain are used. Melzack developed the McGill Pain Questionnaire, and the following scales have been designed to more accurately assess the effects of factors other than nociception: Mental Pain Questionnaire (MPQ), Emory Pain Assessment Model, Minnesota Multiphase Personality Inventory (MMPI), Functional Assessment Screening Questionnaire (FASQ), Pain Disability Index (PDI), Pain Beliefs and Perceptions Inventory, etc. [22]. These types of pain assessment tool require the painstaking examination of conversations and meetings with a patient, which do not completely eliminate the influence of various factors determining the duration of pain. Pain diagnosis is difficult and new tools for assessing pain are needed; therefore, it would be beneficial to identify unambiguous biomarkers of pain. Research to determine pain biomarkers in imaging and laboratory tests should be carried out and advanced [23,24].

3.2. Possibilities of Assessing Serum, Urine and Saliva Pain Biomarkers.

Chronic pain coexists with some psychiatric disorders. Depression and anxiety can lead to chronic pain as well as its persistence [1].

The research made on schizophrenia patients in accordance to pain occurrence seem to be inconclusive. There have been different theories proposed as to pain factors in the disorder. In general it is assumed that pain in individuals with schizophrenia is not significantly different to healthy population. Some cases of analgesia prove rather mental factors and denial attitude to be determinant rather than biological disorder [76].

Some biological biomarkers in plasma such as interleukin-1, interleukin-6, interleukin-10, and tumour necrosis factor-α has been tested in connection with pain experience in psychiatric patients as well as healthy population for reference. It has been concluded that the level of interleukin-1 may be indicative for the occurrence and clinical symptoms of pain. Decreased concentration of interleukin-10 may also be significant for prevalence and clinical appearance of mental disease related pain [77].

Release of pro-inflammatory molecules in microglial such as tumor necrosis factor-α, interleukin 1β, interleukin 6, inducible nitrous oxide synthase (iNOS), and reactive oxygen species influence both chronic pain and cognitive decline in Alzheimer’s disease. Microglial pro-inflammatory activation in brain areas is interceding the affective component of pain and noesis [78].

Elderly patients have an increased risk of suffering from chronic pain. Patients with cognitive impairment particularly with dementia often have difficulties in identifying the level of pain they experience, because of the loss of verbal abilities to express pain. Non-invasive screening of inflammatory pain biomarkers such as
salivary cortisol, salivary α-amylase, secretory IgA (sIgA), testosterone or tumour necrosis factor receptor type II (sTNF-RII) are prospective instruments for detecting the level of pain in elderly population. Apparently, sIgA and sTNF-RII seem to be the most determining factors for pain identification in healthy population [79].

Complex regional pain syndrome (CRPS) is characterized by pain, autonomic responses, hyperalgesia, and allodynia, and is associated with a proinflammatory state[64]. Different inflammatory profiles have been found in acute and chronic cases; in acute case CRPS, there are high levels of interleukin (IL)-8 and soluble tumor necrosis factor receptors, while in chronic phase CRPS, pain is associated with a broad representation of cytokines, NGF, substance P, and calcitonin gene-related peptide (CGRP). The resulting peripheral sensitization with vasodilation and extravasation of proteins explains the peripheral symptoms and severity of clinical symptoms, including increases in interleukin-1, interleukin-6, and tumor necrosis factor α in tissues, blood, and CSF [64,65].

Pain in CRPS is considered to be caused by autoimmunity. The discoveries of self-targeting IgG and IgM analgesic antibodies in CRPS patients have confirmed this hypothesis. Blocking of the NK1 substance P (SP) receptor using a selective LY303870 antagonist has been observed to block CRPS-like nociceptive and vascular changes in CRPS models [65].

Interestingly, many studies have demonstrated the important role of endogenous neurosteroids as pain biomarkers in psychiatric patients. Serum allopregnanolone levels are associated with the incidence of psychiatric disorders and chronic pain in military veterans [80]. Similarly, it has been observed that the occurrence of postmenopausal migraine in depressed women is also associated with low levels of allopregnanolone and normal levels of progesterone and testosterone [81]. In contrast, patients with bipolar disorder and a history of cannabis use had higher serum pregnanolone levels, lower allopregnanolone levels, higher pregnanolone to allopregnanolone ratio, and lower pregnanolone to pregnanolone ratio compared to those with no history of cannabis use. Similar results have not been seen in a history of other substance use disorders, except lower allopregnanolone levels in people with opioid use disorder [82]. Thus, the evaluation of neurosteroid levels as a pain biomarker in psychiatric patients requires further clarification [83].

Another pain disease associated with autoinflammation is cryopyrin-related autoinflammatory syndrome, where the biomarker of pain is the NLRP3 gene, which is responsible for the protein cryopyrin that causes joint and muscle pain. Pain biomarkers in early sarcoidosis are the NOD2 gene and the NOD2 protein that cause joint and tendon pain, including intermittent fever associated with a TNF receptor such as the TNFRSF1A gene and the TNFR1 protein, which are responsible for pain in the muscles and joints, and for headaches [66,67].

A number of studies have evidenced that the primary nutritional, metabolic, and oxidative stressors that cause the development or worsening of chronic pain are not recognized in clinics [69]. Other studies have shown that supplementing these deficiencies reduces pain and improves the functioning of patients with mental problems [70]. Numerous studies have shown that there are strong associations between pain and depression, metabolic deficiencies, and oxidative stress, as well as biomarkers of stress metabolites [69,70,71]. Recently, there have been reports of advanced results in the determination of biomarkers of stress and pain in urine [72].

The Foundation Pain Index (FPI) is a new commercial test resulting from the algorithmic analysis of abnormal urinary metabolites correlated with clinical assessment of chronic pain [72]. FPI results group biomarker profiles in patients with chronic pain and correlate them with clinical symptoms and behavioral assessments of chronic pain [73].
Biomarkers in the FPI study can assess chronic inflammation mediated by cytokines (metabolites of the kynurenine pathway), biomarkers of oxidative stress (pyroglutamic acid, ethyl malonate and hydroxymethylglutarate), as well as micronutrient deficiencies (methylmalonic acid, xanthurenic acid and homocysteine) and neurotransmitters (neuro-transmitters). 5)-hydroxy acids. All biomarkers are directly related to the development, worsening or increase in pain sensation [74].

Experimental studies have demonstrated significant clinical utility of an approved pain biomarker panel that identifies nutritional deficiencies, metabolic abnormalities, and oxidative stressors that lead to treatable causes of pain [72-75].

Table 2. The table shows serum, saliva and urine biomarkers identified in the review

<table>
<thead>
<tr>
<th>Functional biomarkers in serum, urine and saliva</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Quinolinic acid</td>
<td>Elevated in 29% of patients, indicates chronic inflammation mediated by pro-inflammatory cytokines, metabolite of the kynurenic pathway</td>
</tr>
<tr>
<td>Kynurenic acid</td>
<td>Elevated in 27% of patients, indicates chronic inflammation mediated by pro-inflammatory cytokines, metabolite of the kynurenic pathway, supportive marker of chronic pain</td>
</tr>
<tr>
<td>3-hydroxypropyl mercapturic acid</td>
<td>Elevated in 21% of patients, indicator of acrolein exposure to nerve health</td>
</tr>
<tr>
<td>Pyroglutamic acid</td>
<td>Elevated in 19% of patients, indicator of glutathione and oxidative stress</td>
</tr>
<tr>
<td>Xanthurenic acid</td>
<td>Elevated in 17% of patients, marker of vitamin B6 insufficiency</td>
</tr>
<tr>
<td>Homocysteine</td>
<td>Elevated in 11% of patients, indicator of vitamin B6/B9 or B12 deficiency and nerve health</td>
</tr>
<tr>
<td>Hydroxymethylglutarate</td>
<td>Elevated in 11% of patients, Coenzyme Q10 deficiency and oxidative stress</td>
</tr>
<tr>
<td>Methylmalonic acid</td>
<td>Elevated in 10% of patients, indicates low levels of vitamin B12 and nerve health</td>
</tr>
<tr>
<td>Ethylmalonic acid</td>
<td>Increased in 10% of patients, marker of carnitine/vitamin B2 insufficiency, suggests oxidative stress</td>
</tr>
<tr>
<td>Interleukin 8</td>
<td>(I) in acute phase of CRPS [^{64,65}]</td>
</tr>
<tr>
<td><strong>Soluble tumor necrosis factor receptors (sTNFRs)</strong></td>
<td>(I) in acute phase of CRPS(^{[64,65]}); (I) levels in sarcoidosis-related musculoskeletal pain, headaches(^{[66,67]})</td>
</tr>
<tr>
<td>---</td>
<td>---</td>
</tr>
<tr>
<td><strong>NGF (nerve growth factor)</strong></td>
<td>(I) levels in chronic phase of CRPS(^{[64,65]})</td>
</tr>
<tr>
<td><strong>Substance P</strong></td>
<td></td>
</tr>
<tr>
<td><strong>CGRP (calcitonin gene related peptide)</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Inflammatory cytokines spectrum</strong></td>
<td></td>
</tr>
<tr>
<td><strong>NLRP3 gene and cryopyrin</strong></td>
<td>(I) in cryopyrin-related autoinflammatory disease, cryopyrin causes joint and muscle pain(^{[66,67]})</td>
</tr>
<tr>
<td><strong>NOD2 gene and NOD2 protein</strong></td>
<td>(I) in joint and tendon pain in sarcoidosis(^{[66,67]})</td>
</tr>
</tbody>
</table>

### 3.2.1. Biomarker Gene Expression

An important study of pain biomarkers was an advanced research model conducted on psychiatric patients at high risk of comorbid pain disorders and increased pain perception \(^{[68]}\). The expression of putative pain biomarker genes was shown to correlate with pain symptoms; this association was shown for G gamma 7 protein subunit (GNG7), con-tactin 1 (CNTN1), lymphocyte antigen 9 (LY9), helix 144b (CCDC 144b), and guanylate binding protein 1 (GBP1), among others \(^{[71]}\). This study found that GNG7 was a strong predictor of future pain-related emergency room visits, while CNTN1 was a strong predictor of pain intensity. In addition, a new biomarker characterized by the expression of the MFAP3 gene was identified, which, in the literature, had no previous evidence of involvement with pain \(^{[67]}\). Pain biomarkers have been shown to vary based on gender and diagnosis. CNTN1 is associated with chronic pain in women, while LY9 (lymphocyte an-tigen 9) and MFAP3 are associated with pain caused by posttraumatic stress disorder (PTSD) in men.

In addition, the gene expression signature can be used to assess the response to tested drugs, such as SC-560 (NSAID) and amoxapine (an antidepressant), as well as to natural compounds such as pyridoxine (vitamin B6), cyanocobalamin (vitamin B12), and apigenin (a plant flavonoid) \(^{[68]}\).
### Table 3. The table shows promising gene expression pain biomarkers identified in the review.

<table>
<thead>
<tr>
<th>Biomarkers gene expression</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>GNG7 (G Protein Subunit Gamma 7)</td>
<td>(D) in high pain states (HPS), strong predictor of all future pain-related ED visits, involved in chronic pain states (diabetic neuropathy, vertebral disc herniation), high trans-diagnostic evidence of involvement in alcoholism, stress, and hallucinogens abuse[^68]</td>
</tr>
<tr>
<td>CNTN1 (Contactin-1)</td>
<td>(D) in chronic pain states such as chronic widespread pain in women, chronic inflammatory demyelinating polineuropathy, trans-diagnostic evidence of involvement in psychiatric disorders in females.[^68]</td>
</tr>
<tr>
<td>LY9 (lymphocyte antigen 9)</td>
<td>(I) in HPS, good predictor for state and trait, especially for males with PTSD[^68]</td>
</tr>
<tr>
<td>GBP1 (guanylate binding protein 1)</td>
<td>(I) in expression in HPS, predictor for trait in females, (I) in expression in the brain in MDD, schizophrenia and suicidality, and in blood in PTSD patients[^68]</td>
</tr>
<tr>
<td>MFAP3 (microfibril associated protein 3)</td>
<td>(D) in HPS, strong predictor of pain intensity in males and females with PTSD, a novel pain-related gene expression biomarker with no previous evidence in literature[^67]</td>
</tr>
</tbody>
</table>

### 3.3.1. Looking for Pain mediators in the Brain

Recently, studies have proposed new approaches for pain diagnostics using various neuroimaging techniques. These techniques include electroencephalography (EEG), magnetoencephalography (MEG), multiple magnetic resonance imaging (MRI), functional magnetic resonance imaging (fMRI), positron emission tomography (PET), and functional near-infrared spectroscopy (fNIRS), and are aimed at identifying images of markers of pain, namely biomarkers of pain in the brain that can represent structural, functional, and neurochemical changes [25,26].

The anatomical domain of this imaging (e.g., MRI/PET) represents changes in the volume of a part of the brain area involved in chronic pain. The functional domain of imaging (e.g., fMRI) shows the altered dynamic state of the brain in chronic and acute pain, and the chemical domain of imaging (e.g., magnetic resonance spectroscopy, MRS) measures chemical changes in the brain. Studies have shown that, performed together, these three domains make it possible to assess and interpret the presence of chronic pain [27,28].

All of the abovementioned techniques provide noninvasive methods of studying nervous structures in humans. Studies have shown that fMRI provides better temporal and spatial resolution than PET, and nowadays, this method is
more commonly used to measure indirect pain. Nevertheless, it has also been widely reported that pain-related brain activation observed using these functional techniques corresponds to advanced anatomical studies that indicate existing nociceptive connections in the brain [29].

Other studies have developed fMRI patterns that can predict the intensity of a patient’s pain using machine learning analysis. Pattern activity has been demonstrated in areas of the brain that are associated with damaging stimuli pain and include all structures associated with pain stimulus processing, such as the thalamus, anterior and posterior insula, somatosensory cortex, and anterior cingulate cortex [29,30].

Some studies have demonstrated the ability to predict pain from fMRI changes to distinguish painful heat from nonpainful heat. These fNMR studies have also found that there is a difference between physical and social pain and that all fMRI changes are sup-pressed after opioid administration [30,31].

An analysis of the literature reviews on fMRI studies of chronic pain patients indi-cated that an increase in pain can be predicted by signals in the brain’s reward system. The onset of chronic pain involves reorganization of the entire brain network, including at rest. Additionally, fMRI can predict a fixed pain sensation by observing the functional connections of the left fronto-parietal network [32,33].

A new and interesting technology simultaneously measures neural responses to nox-ious stimuli in the central nervous system. Simultaneous corticospinal imaging of brain– spinal interactions demonstrates the role of functional connectivity throughout the brain area in the formation of pain [34].

An alteration in gray matter volume remodeling in patients with a prognosis of chronic pain has also been demonstrated based on voxel morphometric changes in back pain and abnormalities in white matter and brain connectivity [10,34].

Another interesting phenomenon is when anatomical changes reverse after pain re-lief, and therefore, as have reported, anatomical changes may be associated

hyperalgesia was associated with a reduction in the volume of the bilateral area of the hindlimb, the anterior cingulate cortex, and islets [35,36].

Proton magnetic resonance spectroscopy (1H-MRS) in patients with fibromyalgia has shown increased levels of the excitatory neurotransmitter glutamate and decreased levels of GABA (gamma-Aminobutyric acid), inhibitory neurotransmitters in the posterior re-gion insula as compared with healthy subjects [34,37]. This suggests that the posterior part of the insula is a pain-promoting area whose hyperactivity influences of the pain syn-drome [38]. A rat model of neuropathic pain has been shown to generate analogous changes, where increasing glutamate and decreasing GABA levels in the insula resulted in mechanical allodynia [39,40]. Gabapentinoids such as pregabalin have been reported to reduce abnormal glutamate signals in patients with fibromyalgia [41].

According to the literature, the areas of the brain involved in pain processing are the primary and secondary somatosensory cortex, insular cortex (IC), anterior cingulate cor tex (ACC), prefrontal cortex (PFC), thalamus, and cerebellum [10].

The regions for processing emotions, memory, and fear in the amygdala, hippocam-pus, and subcortical structures, including the basal ganglia, are the most frequently acti-vated regions in association with pain signals [40,41].

Acupuncture pain studies have shown that the gray periapical area (PAG) is one area that is activated by most pain mechanisms. Interestingly, various ventromedial atrial ac-tivity known to carry descending PAG modulation was observed during both acupunc-ture anesthesia and anxiety-induced hyperalgesia. Other areas of the brain that appear to be involved in pain mechanisms, such as the anterior cingulate cortex, prefrontal cortex, orbitofrontal cortex, and nucleus accumbens were not activated simultaneously in these patients [42,43].
Due to the increase in pain complaints and significant impairment of functioning, many studies have been conducted on quick diagnostic methods by determining pain biomarkers in complex regional pain syndrome (CRPS) [43].

In adults and children, complex regional pain syndrome (CRPS) develops in parts of the body after an injury, stroke, sprain, or fracture. There are often pathological changes in bone and skin, as well as extreme sensitivity to touch, known as allodynia. The condition is thought to be a malfunctioning of the peripheral and central antinociceptive system. Early correct diagnosis is thought to be important for preventing progression, and therefore avoiding a long-lasting disability [44].

In patients with CRPS, CNS fMRI imaging showed an association of pain with activation of connections between the middle prefrontal cortex (MPFC), cingulate gyrus, and the lower parietal lobe. Increased connectivity of MPFCs with insular cortex has also been demonstrated with increasing symptoms.

Resting fMRI showed gray matter atrophy in the right islet, right ventromedial prefrontal cortex (VMPFC), and right nucleus accumbens in CRPS patients [44]. Similarly, 18F-FDG-PET (Positron Emission Tomography with fluorodeoxyglucose F 18) has been used to show increased glucose metabolism in many pain-related brain regions; magnetoencephalographic (MEG) studies at rest have demonstrated abnormal electrophysiology in the orbitofrontal-temporal cortices and somatosensory cortex, which, respectively, hint at deficits in affective pain perception and pain localization in CRPS patients [44].

According to the literature on proton magnetic resonance spectroscopy (1H-MRS), depleted levels of N-acetylaspartate (a marker of neuronal density) and other identifiable chemicals relative to creatine in four bilateral brain regions (the dorsolateral prefrontal cortex, orbitofrontal cortex, cingulate, and thalamus) can be a marker for CRPS syndrome [45].

Another fMRI study found functional abnormalities in the thalamus and primary somatosensory cortex (S1) of the brain. As expected, CRPS patients showed poor acuity of painful limb touch related to the strength of functional thalamo-S1 connectivity. CRPS subjects displayed stronger thalamo-S1 functional connectivity than controls, and this was related to the intensity of the pain [46].

With a magnetic field scan performed by standard MR sequences (T1-weighted and T2-weighted images, 3D FLAIR, DWI, and ADC sequences) and 1H-MRS, it is possible to assess metabolites by microglial activation. N-acetylaspartate (NAA, a marker of neuronal density), choline (Cho, an indicator of myelin breakdown products, building the sheaths of nerve cells), and myo-inositol (mI) are considered to be markers of microglial activation. Using the single voxel spectroscopy (SVS) method, it has been possible to assess the differences between both hemispheres of the brain in CRPS patients at the following locations: insula, thalamus, basal ganglia, and postcentral gyrus [11–14,46].

Single voxel 1H-MRS is a noninvasive method for in vivo quantification of several different brain metabolites including N-acetylaspartate (NAA, a marker of neuronal density), choline-containing compounds (Cho, an indicator of myelin breakdown products, building the sheaths of nerve cells), creatine (Cr, energy metabolism marker), myo-inositol (mI, a marker of microglia activation) and glutamate-glutamine (Glx, excitatory neurotransmitter and precursor amino acid). The advantage of this method is that it may provide information about metabolic alterations in the brain, while MRI fails to reveal any morphological abnormalities. The 1H-MRS study showed changes in the presence of metabolites in patients with CRPS. The spectrum from basal ganglia on the diseased side of 1H-MRS showed
a marked increase in choline (Cho) and a relative decrease in N-acetyl aspartate (NAA) compared to the spectral levels of creatine [47].

A reduced level of N-acetylaspartate in the bilateral dorsolateral prefrontal cortex and an increased level of myo-inositol (a marker of activated microglia) in the left orbito-frontal cortex of a patient with intractable severe pain were found also in another CRPS study [48].

Machine learning techniques are increasingly used in functional imaging studies, including for pain recognition. Examination used EEG analysis to assess the potential analgesic response to morphine administration. Machine learning based on electroencephalography, applied to patients in the pain-free period before treatment, has enabled an algorithm to separate responders from non-responders [49, 50].

Structural and functional magnetic resonance imaging analyzed by multivariate pattern analysis (MVPA) can accurately distinguish between people with Musculoskeletal Pain and healthy people [51]. The main network identified by the MVPA is the neurological pain signature (NPS) [10, 52, 53], which is sensitive and specific to pain in individuals and involves brain regions that receive afferents nociceptive information [54]. The NPS is promisingly accurate for noxious stimuli but does not correctly capture all effects, i.e., the effects of cognitive regulation and the effects of perceived control on pain [54].

A new tool [54] evaluates the multivariate fMRI signature, termed stimulus intensity independent pain signature-1 (SIIPS1), and can predict changes in pain above and beyond the noxious stimulus intensity and the nociceptive brain processes estimated by NPS [53–55].

This interesting study shows that both social information and individual learning independently influence the perception of pain [54]. The brain regions involved in pain modification are very different. The limbic and posterior regions of the brain mediate conditioning effects, while the prefrontal and parietal regions more strongly mediate the impact of social information on pain. Taken together, these results suggest that top-down modulation of experience may come from diffuse sources in the frontoparietal and limbic regions, depending on the source of information [52, 54]. Expectations caused by social influence and instructions can be especially powerful in shaping perceptions and experiences by bypassing learning networks and directly engaging in fused higher-level pre-frontal and parietal areas. Taken together, these results suggest that top-down modulation of experience may come from diffuse sources in the frontoparietal and limbic regions, depending on the sources of information [54]. These works showed that the psychological effect of pain is very complex and, at the same time, dispersed in the structures of the CNS.

Although no clear central representation has been identified, pain treatment can be observed by signature like as biomarkers. A double-blind, randomized, placebo-controlled, three-way crossover study with fMRI in a sensitization model in a healthy volunteer generated a signature database and correctly differentiated between decreased gabapentin and brain pain response [55]. However, in real life, excessive consumption of gabapentinoids has been observed despite a good analgesic effect [55]. Moreover, emotional pain is just as important to the patient and should not be considered to be “second-class” pain, although it is difficult to understand and diagnose. Machine learning methods that generate emotional pain signatures/biomarkers that have their own specificity and sensitivity would be diagnostically helpful in this regard [54–55]. Unfortunately, such a procedure is not universal, and a complete clinical evaluation is still required in the assessment of chronic pain [10].
One method of neuroimaging is functional near infrared spectroscopy (fNIRS) [56]. It is a noninvasive technology that indicates brain activity in areas underneath sensors and can measure the activity of the cerebral cortex in response to painful stimulation. The advantage of fNIRS is that it can be used in real clinical conditions, where it is mainly used to assess the metabolism of the frontal lobes by reading oxygenation of the brain tissue and blood flow hemodynamics. Due to its noninvasiveness, fNIRS is used in a variety of clinical settings, including operating theaters, patient rooms, and experimental settings. The use of fNIRS has been demonstrated to assess pain in response to various types of thermal stimulation with high measurement accuracy [56].

3.3.2. Emotions Alter Nociceptive Responsiveness

Neuroimaging biomarkers can be used to assess the influence of emotions on the development of pain. An fNMR study showed that a subject’s observation of frightened facial expressions caused discomfort and anxiety with simultaneous activation of pain neurons in the ACC [10,57,58].

Several studies have shown a parallel effect of the state of attention and mood on the perception of pain. In one study, subjects were allowed to alternate between a painful stimulus and a smell presented at the same time; by manipulating mood and attention, a activation of pain neurons in the ACC was demonstrated [59,60,61].

Increased neuronal activity in the ACC and the accompanying activation of other individual pain areas in the brain have also been demonstrated as a result of changes in a patient’s mood under the influence of reading and listening to sad comments and music. It has been observed that changes in negative emotions caused by auditory stimuli result in increased activity of pain areas in the frontal lobe as well as the ACC and hippocampus [10,62,63,64].

The activity of pain-related neurons of the brain, such as the brain’s limbic system, ACC, frontal cortex, and hippocampus, is a biomarker for both pain and the emotional changes that cause pain. Pharmacological modulation of the nerve pathways involved in emotional transmission modulates the perception of pain, and the condition can also be monitored using neuroimaging. For example, in neuroimaging, opiate-sensitive pathways from the frontal cortex to the amygdala, PAG, ventral spinal cord (RVM), and dorsal atrium have been shown to be involved in the attention-dependent modulation of pain [25,65,66].

Using functional connectivity analysis, it has been shown [66] that the fronto-PAG circuits are associated with the emotional component of pain, and changes in the upper parietal lobe, which is part of the attention orientation system, can be modulated by pain. In the same work, using fNRM neuroimaging, descending pathways of pain modulation were distinguished, which are responsible for the psychological modulation of pain [51,56].

The nerve pathways involved in pain, from the ACC to the PFC, and then to the PAG, and the island pathway through the amygdala body to the PAG have been identified as less prone to modulation and alteration of the pain signal than the ascending pathways [28].
### Table 4. This table shows possible pain biomarkers that can be found in neuroimaging.

<table>
<thead>
<tr>
<th>Biomarkers in neuroimaging</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>1H-MRS of the brain (proton magnetic resonance spectroscopy)</td>
<td>In fibromyalgia patients: increased (I) levels of glutamate and decreased (D) levels of GABA in insula, which suggests that it is pain-promoting region of the brain [34,37]</td>
</tr>
<tr>
<td></td>
<td>In CRPS (complex regional pain syndrome): in basal ganglia on the diseased side – (I) choline, (D) NAA [45,47]; (D) NAA in bilateral dorsolateral prefrontal cortex, (I) level of myo-inositol in left orbitofrontal cortex [48]</td>
</tr>
<tr>
<td>fMRI (functional magnetic resonance)</td>
<td>In mechanical hyperalgesia: reduction of volume of the bilateral hindlimb area, anterior cingulate cortex, islets [35,36]</td>
</tr>
<tr>
<td></td>
<td>Gray peripheral area (PAG) is activated by most pain mechanisms [42,43]</td>
</tr>
<tr>
<td></td>
<td>In CRPS: pain is associated with (I) connectivity between MPFC, cingulate gyrus, lower parietal lobe, (I) connectivity between MPFC and insular cortex; (I) activity in connection between thalamus and primary somatosensory cortex [46], gray matter atrophy in right islet, right VMPFC, right nucleus accumbens [44]</td>
</tr>
<tr>
<td>fNIRS (functional near infrared spectroscopy)</td>
<td>(I) metabolism of frontal lobes measured by oxygenation and blood flow, fNIRS measurement shown good accuracy in assessing pain in response to thermal nociceptive stimulation [56]</td>
</tr>
</tbody>
</table>

### 4. Conclusions

Pain is a complex experience, which includes somatic, affective, cognitive, and behavioural features, all of which are the result of mental processes, and therefore represents a psychological condition. Chronic pain is very difficult to evaluate, and even harder to heal, because the memory of it and accompanying emotions last for many years. Therefore, many diagnostic and therapeutic schemas, biomarkers, and algorithms have been introduced to adequately control pain. Patients with mental disorders and diseases who do not exhibit patterns in the diagnosis and therapy processes present a problem. Therefore, the treatment of chronic pain should be a comprehensive procedure, in which specialists from various fields of medicine, including psychologists, psychiatrists, social workers,
and educators, are involved in the process of diagnosis and therapy. Such a comprehensive therapy gives hope for proper and effective pain treatment. Information regarding the developed and standardized pain biomarkers is extremely helpful in this process but does not replace comprehensive clinical assessment.

There are some limitations to this study that are inherent in any systematic review. First, the study has a relatively small selection of studies, and the included studies have tended to be small, limiting the generalization of results. Second, the review is narrative, without sophisticated data analysis methods, without a clear ranking of causality, or an attempt to establish a decision threshold above which "pain biomarkers" can accurately identify the type of pain and its possible cause.

Other biomarkers, such as the use of endogenous neurosteroids as pain biomarkers in psychiatric patients, were also not included in the summary. Although very promising in the absence of randomized review studies, they were not included in this review.

In conclusion, although research into the determination of pain biomarkers is very advanced, it is impossible to diagnose and differentiate pain using these techniques routinely. The history and clinical examination remain invaluable. The search for further research is necessary for the coming years.

In clinical trials, it is possible to distinguish pain biomarkers in mental diseases both at the level of body fluid testing, neuroimaging, and genetic testing, which may, in individual selected cases, facilitate the correct diagnosis and isolate the pathophysiology of pain.

Author Contributions: Conceptualization, P.J.; Writing - Original Draft Preparation, P.J. and U.K.; Writing—Review & Editing, P.J., U.K., A.G., AT, and M.M. reviewed the literature. M.M. is head of the Independent Department Laboratory of Molecular Imaging. All authors have read and agreed to the published version of the manuscript. PJ is the guarantor of this work.

Funding: This research received no external funding.

Institutional Review Board Statement: Not applicable for studies not involving humans or animals, study did not require ethical approval.

Informed Consent Statement: Not applicable for studies not involving humans.

Conflicts of Interest: The authors declare no conflicts of interest.

References


